RMIT researchers have created an experimental 3D-printed diamond–titanium device that generates electricity from flowing liquid and receives wireless power through tissue making it possible to remotely sense changes in flow.
As a wound heals, it goes through several stages: clotting to stop bleeding, immune system response, scabbing, and scarring. A wearable device called “a-Heal,” designed by engineers at the University of California, Santa Cruz, aims to optimize each stage of the process.
Maintaining balance while walking may seem automatic—until suddenly it isn’t. Gait impairment, or difficulty with walking, is a major liability for stroke and Parkinson’s patients. Not only do gait issues slow a person down, but they are also one of the top causes of falls. And solutions are often limited to time-intensive and costly physical therapy.
The expanded clearance extends BioTraceIO360 beyond liver applications to kidney procedures, advancing Techsomed’s vision of a multi-organ, AI-driven image-guided therapy platform that standardises minimally invasive cancer care.
Picard Medical (NYSE:PMI) announced today that it expanded its IP portfolio with a new U.S. patent for its next-generation artificial heart.
Cionic announced today that the FDA granted clearance for its second-generation product, the Neural Sleeve 2.
Virtuoso Surgical announced today that it received FDA breakthrough device designation for bladder lesion removal with its surgical robot.
Heartflow (Nasdaq:HTFL) announced that it received FDA 510(k) clearance for its next-generation Heartflow Plaque Analysis algorithm.
GRAND RAPIDS, Mich., Sept. 22, 2025 /PRNewswire/ — Shoulder Innovations, Inc. (Shoulder Innovations, or the company) (NYSE: SI), a commercial-stage medical technology company exclusively focused on transforming the shoulder surgical care market, today announced the full commercial launch of the InSet™ 70 Humeral Stem (“InSet™ 70”).
SAN DIEGO, Sept. 22, 2025 /PRNewswire/ — Building on its leadership in point-of-care diagnostic testing, QuidelOrtho Corporation (Nasdaq: QDEL) (“QuidelOrtho”), a leading global provider of innovative in vitro diagnostic technologies, is expanding its QUICKVUE portfolio with the QUICKVUE Influenza + SARS Test, a CLIA-waived, 510(k)–cleared rapid, easy-to-use immunoassay designed for professional use in physician office laboratories, urgent care centers, emergency departments, pharmacies and decentralized hospital labs.